I-Blinatumomab: ye-acute lymphoblastic leukemia
-Delile
I-Blinatumomab yisidakamizwa esingajova esisebenza njenge-antibody, esibopha ulwelwesi lwamangqamuzana omdlavuza futhi siwavumele ukuthi abonakale kalula amasosha omzimba. Ngakho-ke, amangqamuzana okuvikela anesikhathi esilula ukuqeda amangqamuzana omdlavuza, ikakhulukazi esimweni se-acute lymphoblastic leukemia.
Lo muthi futhi ungaziwa ngokuthengisa njengeBlincyto futhi kufanele usetshenziswe kuphela esibhedlela ekwelashweni komdlavuza, ngaphansi kokuqondiswa ngudokotela oncologist.
Intengo
Lo muthi awunakuthengwa kuma-pharmacy ajwayelekile, usetshenziswa kuphela ngesikhathi sokwelapha umdlavuza esibhedlela noma ezikhungweni ezikhethekile, njenge-INCA, ngokwesibonelo.
Yenzelwe ini
I-Blinatumomab ikhonjisiwe ekwelashweni kwe-acute precursor B-cell lymphoblastic leukemia, Philadelphia chromosome negative, in relapse or refractory.
Isetshenziswa kanjani
Umthamo we-blinatumomab okufanele uphathwe kufanele uhlale uqondiswa yi-oncologist, njengoba yehluka ngokuya ngezimpawu zomuntu nesigaba sokuvela kwesifo.
Ukwelashwa kwenziwa ngemijikelezo emi-2 yamaviki ama-4 lilinye, ihlukaniswe ngamaviki ama-2, futhi kufanele ulaliswe esibhedlela phakathi nezinsuku eziyi-9 zokuqala zomjikelezo wokuqala nezinsuku ezi-2 zomjikelezo wesibili.
Imiphumela emibi engaba khona
Imiphumela emibi ejwayelekile yokusebenzisa leli khambi ifaka i-anemia, ukukhathala ngokweqile, umfutho ophansi wegazi, ukuqwasha, ikhanda, ukundindizela, isiyezi, ukukhwehlela, isicanucanu, ukuhlanza, ukuqunjelwa, ubuhlungu besisu, ubuhlungu beqolo, imfiva, ubuhlungu emalungeni, ukugodola izinguquko ekuhlolweni kwegazi.
Ngubani ongafanele asebenzise
I-Blinatumomab iyaphikiswa kwabesifazane abancancisayo kanye nabantu abanezifo ezithile zomzimba kunoma yiziphi izingxenye zefomula. Ngaphezu kwalokho, esimweni sabesifazane abakhulelwe, kufanele isetshenziswe kuphela ngaphansi kokuqondiswa kukabeletha.